This comprehensive report entitled Global DNA Vaccine Market Outlook 2022 provides an in-depth analysis of the global DNA Vaccines market, presenting readers with a profound understanding of the various challenges, drivers, and developments in this industry.
The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines. Various vaccines have been introduced in the market based on this technique.
Some of the major DNA vaccines include GlaxoSmithKline's Engerix-B, Twinrix, and Fendrix; Merck's Gardasil, and Recombivax HB; Protein Sciences Corporation's Flublok, etc. Currently, the researchers are engaged in developing genetic vaccines for humans. Animal genetic vaccines are already present in the market. These vaccines are third generation vaccines and contain DNA that codes for specific proteins from a pathogen. This DNA is injected into host body and produces protein for which the body generates immune response.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. DNA Vaccine - An Introduction
4. Drivers & Challenges
5. DNA Vaccine Market Overview
6. DNA Vaccines Market by Geography
7. DNA Vaccine Market by Type
8. DNA Vaccines Market by End User
9. DNA Vaccines Market by Therapeutic Indication
10. Pipeline Analysis
12. Company Profiles
- Novartis International AG
- Merck & Co., Inc
- GlaxoSmithKline plc.
- Green Cross Corporation
- Inovio Pharmaceuticals, Inc.,
- Bharat Biotech
- Protein Sciences Corporation
- Indian Immunologicals Ltd.
- Serum Institute of India Pvt. Ltd
For more information about this report visit https://www.researchandmarkets.com/research/b2l2rh/global_dna?w=4